Nedaplatin

Nedaplatin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC2H8N2O3Pt
Molar mass303.181 g·mol−1
3D model (JSmol)
  • C(C(=O)[O-])[O-].N.N.[Pt+2]

  • coordination form: O=C1O[Pt-2]([NH3+])([NH3+])OC1
  • InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1
  • Key:GYAVMUDJCHAASE-UHFFFAOYSA-M
  (verify)

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.

Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.[2]

  1. ^ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219-33. doi:10.1530/ERC-15-0237. hdl:2123/24426. PMID 26113607.
  2. ^ Johnstone TC, Park GY, Lippard SJ (January 2014). "Understanding and improving platinum anticancer drugs--phenanthriplatin". Anticancer Research. 34 (1): 471–6. PMC 3937549. PMID 24403503.